Lost Money on ADMA BIOLOGICS, INC. (ADMA)? Join Class Action Suit Seeking Recovery - Contact SueWallSt
Levi & Korsinsky LLP, operating as SueWallSt, issued a solicitation for investors to join a class action lawsuit against ADMA Biologics regarding alleged securities fraud between August 2024 and March 2026. The complaint alleges ADMA engaged in channel stuffing to inflate ASCENIV revenue figures, reporting 20% growth when independent research suggests a 3% decline.
Key figures
- Pricing premium
- $900/gram
- Reported yoy growth
- 20%
- Asceniv 2023 revenue
- $92.6 million
- Estimated real yoy growth
- -3%
- Asceniv 2025 reported revenue
- $362.5 million
- Related party purchases range
- $0.1 million to $0.4 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.